The numbers, to scale
All four quarters, fee-for-service and managed care combined. Source: CMS State Drug Utilization Data 2025, updated July 13, 2026.
CMS national totals for the same products, each year's full dataset.
Every state (52), most prescriptions first
| State | Prescriptions | Share | Top product |
|---|---|---|---|
| California | 3,089,327 | 27.4% | Wegovy |
| Pennsylvania | 843,743 | 7.5% | Wegovy |
| New York | 815,882 | 7.2% | Ozempic |
| Michigan | 607,982 | 5.4% | Wegovy |
| North Carolina | 484,401 | 4.3% | Wegovy |
| Ohio | 425,143 | 3.8% | Trulicity |
| Massachusetts | 399,014 | 3.5% | Zepbound |
| Wisconsin | 302,633 | 2.7% | Zepbound |
| Illinois | 288,470 | 2.6% | Trulicity |
| Missouri | 285,105 | 2.5% | Zepbound |
| Kentucky | 274,170 | 2.4% | Ozempic |
| Minnesota | 230,594 | 2.0% | Wegovy |
| Louisiana | 230,117 | 2.0% | Mounjaro |
| Virginia | 227,472 | 2.0% | Trulicity |
| Indiana | 190,013 | 1.7% | Ozempic |
| Connecticut | 174,430 | 1.5% | Ozempic |
| Texas | 172,203 | 1.5% | Ozempic |
| New Jersey | 165,515 | 1.5% | Ozempic |
| Maryland | 148,487 | 1.3% | Ozempic |
| Tennessee | 135,961 | 1.2% | Ozempic |
| Florida | 133,402 | 1.2% | Ozempic |
| Colorado | 123,001 | 1.1% | Trulicity |
| Washington | 111,160 | 1.0% | Liraglutide (generic) |
| West Virginia | 94,999 | 0.8% | Ozempic |
| Arizona | 93,519 | 0.8% | Trulicity |
| Iowa | 88,518 | 0.8% | Ozempic |
| Oklahoma | 82,353 | 0.7% | Trulicity |
| Oregon | 72,779 | 0.6% | Ozempic |
| Alabama | 71,772 | 0.6% | Ozempic |
| Nevada | 70,791 | 0.6% | Ozempic |
| South Carolina | 65,093 | 0.6% | Ozempic |
| New Mexico | 64,832 | 0.6% | Ozempic |
| Mississippi | 61,646 | 0.5% | Wegovy |
| Georgia | 59,336 | 0.5% | Ozempic |
| Delaware | 55,674 | 0.5% | Wegovy |
| Kansas | 50,850 | 0.5% | Zepbound |
| Puerto Rico | 48,732 | 0.4% | Trulicity |
| Rhode Island | 46,691 | 0.4% | Ozempic |
| Idaho | 45,954 | 0.4% | Ozempic |
| Maine | 41,655 | 0.4% | Trulicity |
| Nebraska | 37,324 | 0.3% | Ozempic |
| New Hampshire | 34,652 | 0.3% | Wegovy |
| Hawaii | 30,455 | 0.3% | Ozempic |
| Utah | 27,850 | 0.2% | Ozempic |
| District of Columbia | 27,754 | 0.2% | Ozempic |
| Arkansas | 24,039 | 0.2% | Liraglutide (generic) |
| Alaska | 23,225 | 0.2% | Ozempic |
| Montana | 22,719 | 0.2% | Ozempic |
| Vermont | 17,163 | 0.2% | Ozempic |
| South Dakota | 15,521 | 0.1% | Mounjaro |
| North Dakota | 5,852 | 0.1% | Liraglutide (generic) |
| Wyoming | 2,315 | 0.0% | Trulicity |
Sums of every unsuppressed state row for the products in the method. "Share" is of the CMS national total (11.26 million). All 52 rows, with every column, are in the CSV and JSON.
How the number is computed
Sum of "Number of Prescriptions" across all four quarters of 2025, both utilization types (fee-for-service and managed care), for every GLP-1 product NDC. The national figure is CMS's own national row (state code XX); state figures sum each state's rows.
Included
- Products: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Liraglutide (generic), Byetta, Bydureon, Exenatide (generic), Adlyxin.
Excluded
- Insulin combinations: Soliqua (insulin glargine and lixisenatide); Xultophy (insulin degludec and liraglutide).
- Rows CMS suppressed for privacy (under 11 prescriptions).
Read it with care
- Reimbursement is what Medicaid paid pharmacies, before the manufacturer rebates states receive; CMS does not publish net cost per drug.
- CMS suppresses any row with fewer than 11 prescriptions; those rows count as zero here, so small states and small products are undercounted slightly.
- Totals reflect state program size as much as use: no per-enrollee rate is published in this dataset.
- State figures are as reported by the states and can be revised by CMS.
Receipts
2 sources · read October 4, 2026
- 01read
497 national and 11,913 state rows for the GLP-1 products listed in the method.
CMS, State Drug Utilization Data 2025 (data.medicaid.gov), updated July 13, 2026 - 02read
Amounts are reimbursements before rebates; counts under 11 are suppressed.
CMS, State Drug Utilization Data: about the data
Cite this
Free to reuse under CC BY 4.0: quote the number, credit PriceTracker GLP-1 with a link, and name the federal source. The underlying records are public; our counts, matching and files are the work you are crediting.
PriceTracker GLP-1. (2026, October 4). Medicaid GLP-1 prescriptions by state, 2025 [Data set]. Based on Centers for Medicare & Medicaid Services data, cms data updated July 13, 2026. https://pricetrackerglp1.com/data/medicaid-glp1-prescriptions-by-state
<p>State Medicaid programs paid for 11.26 million GLP-1 prescriptions in 2025, California the most at 3.09 million, according to CMS State Drug Utilization Data updated July 13, 2026. Source: <a href="https://pricetrackerglp1.com/data/medicaid-glp1-prescriptions-by-state">PriceTracker GLP-1</a> (CC BY 4.0).</p>
https://pricetrackerglp1.com/data/medicaid-glp1-prescriptions-by-state.csv https://pricetrackerglp1.com/data/medicaid-glp1-prescriptions-by-state.json